Biogen/Elan Antegren Crohn’s Plans Await Talks With FDA After Trial Fails
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The need for additional studies for Biogen/Elan’s Antegren in Crohn’s disease could hinge upon FDA’s acceptance of data from secondary endpoints or subgroup analysis of the ENACT-1 pivotal trial.
You may also be interested in...
Monoclonal Antibodies For Inflammatory Bowel Disease Prominent At DDW
Many firms involved in bowel disease drug development are seeking to identify subpopulations where new therapies can show activity, late-stage clinical data presented at the Digestive Disease Week meeting in New Orleans May 15-20 indicate.
Elan Antegren Strategy: Separate Crohn’s Maintenance And Induction Claims
Elan/Biogen Idec’s regulatory strategy for gaining approval of Antegren (natalizumab) for Crohn’s disease appears to be centered on separating indications for induction and maintenance therapy.
Elan Antegren Strategy: Separate Crohn’s Maintenance And Induction Claims
Elan/Biogen Idec’s regulatory strategy for gaining approval of Antegren (natalizumab) for Crohn’s disease appears to be centered on separating indications for induction and maintenance therapy.